Bevacizumab/cetuximab/irinotecanDevelopment of chemotherapy resistance and disease progression: 4 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2015年 / 1533卷 / 1期

关键词：

D O I：

10.1007/s40278-015-6105-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：87 / 87

相关论文

共 50 条

[1] Bevacizumab/enalapril/perindopril/ramiprilHypertension and disease progression: 3 case reports
Reactions Weekly, 2015, 1550 (1) : 40 - 40
[2] Bevacizumab/paclitaxelDysphonia: 4 case reports
Reactions Weekly, 2014, 1518 (1) : 47 - 47
[3] Bevacizumab/cetuximabDrug resistance: 2 case reports
Reactions Weekly, 2020, 1799 (1) : 98 - 98
[4] Cetuximab/dabrafenib/trametinibDrug resistance: 2 case reports
Reactions Weekly, 2020, 1823 (1) : 118 - 118
[5] Cetuximab/imatinib/sunitinibAcquired resistance: 3 case reports
Reactions Weekly, 2022, 1932 (1) : 177 - 177
[6] NeratinibAcquired drug resistance leading to disease progression: 2 case reports
Reactions Weekly, 2022, 1902 (1) : 345 - 345
[7] IbrutinibDevelopment of resistance mutations leading to disease progression: 2 case reports
Reactions Weekly, 2019, 1738 (1) : 144 - 144
[8] Multiple drugsLack of efficacy or disease progression: 4 case reports
Reactions Weekly, 2022, 1917 (1) : 400 - 400
[9] Bevacizumab/pazopanibVarious toxicities: 4 case reports
Reactions Weekly, 2019, 1758 (1) : 79 - 79
[10] Bevacizumab/paclitaxelVarious toxicities: 4 case reports
Reactions Weekly, 2021, 1844 (1) : 94 - 94

← 1 2 3 4 5 →